Verapamil is extremely effective in the treatment of patients with hypertrophic cardiomyopathy. However, the basic physiologic actions of the drug may lead to serious adverse effects. An appreciation of this and an understanding of when these adverse effects are most likely to occur will minimize the potential of verapamil to cause serious complications in patients with hypertrophic cardiomyopathy.
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VERAPAMIL is an important drug for treating symptomatic patients with hypertrophic cardiomyopathy.'-3 As with many potent drugs, it does have the potential of adverse actions. These adverse actions might be exacerbated in patients with hypertrophic cardiomyopathy by the dynamic nature of the left ventricular outflow obstruction peculiar to such patients. In the past 3 years we have administered verapamil to 120 patients with hypertrophic cardiomyopathy. Although the incidence of serious or potentially serious complications was relatively low, the fact that they occurred has caused us concern. The impetus for this review derives both from our concern about these occasional clinically important hemodynamic complications and from the fact that verapamil is being used much more often to treat patients with hypertrophic cardiomyopathy.
The absolute number of verapamil-induced complications we have observed is small. Therefore, this paper consists of a theoretical analysis of how the known electrophysiologic and hemodynamic actions of verapamil might result in deleterious effects in patients with hypertrophic cardiomyopathy, and brief, largely anecdotal presentations of the actual complications we have observed, which illustrate that the theoretical potential for verapamil to cause deleterious effects may indeed lead to serious complications in susceptible patients.
Patient Selection and Verapamil Dosage
Our criteria for deciding which patients with hypertrophic cardiomyopathy should receive the drug have been detailed2 and are based mainly on unsatisfactory control of symptoms with propranolol. Verapamil dosages have also been detailed.23' Patients are usually started in-hospital on 80 mg every 8 hours; if no adverse side effects occur after 48 hours, the dose is increased to 120 mg every 8 hours. Higher doses (up to 720 mg/day) are used during follow-up if complications have not occurred and if symptoms have not been adequately controlled on the standard dose.
Suppression of Sinus Node Automaticity and Inhibition of Atrioventricular Nodal Conduction
The incidence and type of these complications in our series are listed in table 1. Verapamil directly suppresses sinus node pacemaker activity and is one of the most potent inhibitors of atrioventricular (AV) nodal conduction.4'6 Usually, depression of the sinus node is not evident because the hypotensive actions of the drug lead to baroreceptor-mediated reflex changes of autonomic tone to the sinus node (sympathetic stimulation and parasympathetic withdrawal), minimizing any tendency toward sinus slowing. Commonly, however, sinus node depression becomes evident. Most often it manifests itself as mild bradycardia, usually associated with a junctional escape rhythm that superficially resembles complete AV block, but which on further analysis can be identified as isorhythmic dissociation ( fig. 1 ). Rarely, sinus arrest appears,2 although this complication probably occurs mostly in patients with underlying abnormalities of sinus node pacemaker activity.
The first clinical sign of an electrophysiologic effect is usually prolongation of AV nodal conduction, manifest by PR prolongation on the ECG.7' 8 In high enough doses, however, verapamil may lead to complete AV block.6' 9, 10 Verapamil does not appear to inhibit all forms ofjunctional automaticity,6 so it can be expected that a junctional rhythm will emerge at a reasonable rate. Nonetheless, patients with hypertrophic cardiomyopathy are singularly susceptible to abnormalities that produce AV dissociation. Because of the diminished compliance of the left ventricle in this disease, loss of a synchronized contribution of atrial contraction to ventricular filling can lead to hypotension which, in turn, could cause an increase in obstruction to left ventricular outflow. A vicious cycle is established, leading to further hypotension, further obstruction, and so on. The potent vasodilatory actions of verapamil would only exacerbate this sequence of events. Vasodilatation Verapamil, administered intravenously to patients in the cardiac catheterization laboratory, usually diminishes the gradient in patients with hypertrophic cardiomyopathy who have obstruction to left ventricular outflow.8 However, excessive vasodilatation may lead to serious hemodynamic consequences. Thus, if verapamil causes a marked drop in blood pressure, a paradoxical increase in left ventricular outflow obstruction can occur. The mechanisms responsible for this presumably derive from both the decrease in afterload and the resulting reflex increase in sympathetic stimulation to the heart. Each of these actions, by increasing the velocity of left ventricular ejection, can exacerbate the gradient.'1 Figure 2 is an example of this occurring in the catheterization laboratory after i.v. verapamil. As systemic systolic blood pressure decreased from 160 to 105 mm Hg, the left ventricular outflow tract gradient increased from 35 to approximately 80 mm Hg. Although the gradient quickly returned to control values in this patient after cessation of verapamil infusion, it is easily appreciated how the combination of a large decrease in blood pressure (with associated decrease in coronary perfusion pressure) and high in- This sequence of events probably occurred in at least two patients in whom verapamil was given orally. Patient JJU (table 2) developed lightheadedness and near-syncope when arising from bed. Systolic blood pressure was 70 mm Hg and shortly thereafter, frank pulmonary edema developed. This occurred in the hospital after his thirteenth dose of oral verapamil (80 mg three times per day for six doses, and 120 mg three times per day for seven doses). This patient also was taking quinidine at the time verapamil was begun. Patient PS had a similar episode. When this patient's blood pressure decreased on verapamil (from control values of 150/100 to 110/70 mm Hg), the intensity of his murmur increased, suggesting increased left ventricular outflow obstruction. These changes were accompanied by more severe shortness of breath and an increase in pulmonary artery wedge pressure from 20 to 32 mm Hg. In addition to these more serious complications, administration of verapamil orally was associated with postural hypotension, which did not lead to any congestive symptoms in three other patients (3%).
Negative Inotropic Effects
Verapamil can decrease myocardial contractility in vitro at high concentration.'2' 13 Although some studies have demonstrated verapamil-induced depression in contractility in vivo,9' 1 other studies have failed to elicit such an effect."'-"7 These conflicting results may be a consequence of different drug doses, different experimental models, and differences in the relative contributions of the direct and indirect actions of verapamil.
We have used radionuclide cineangiography to measure changes in contractile function and found that neither left ventricular ejection fraction nor rate of ejection was altered by verapamil in patients with hypertrophic cardiomyopathy.'8 Although this sug-gests that verapamil does not usually depress myocardial function in patients with hypertrophic cardiomyopathy, we have seen two patients (patient JH and one patient treated since this study was completed) who had no left ventricular outflow tract obstruction, but nonetheless developed pulmonary edema after administration of oral verapamil. Another patient without obstruction developed pulmonary edema while on oral nifedipine. In these patients without obstruction, the most likely mechanism of the development of pulmonary edema is a drug-induced deterioration of left ventricular contractile function. Hence, although clinically important hemodynamic complications caused by the negative inotropic potential of calcium channel blocking agents are uncommon, such complications probably can occur. Figure 3 is a summary of the potential ways in which verapamil could lead to sudden death in patients with hypertrophic cardiomyopathy. The major factor predisposing to verapamil-induced death is based on the sensitivity of patients with the obstructive form of the disease to hypotension; a decrease in systemic pressure can increase obstruction to left ventricular outflow by both decreasing afterload and reflexly increasing sympathetic stimulation to the heart. The result is systemic hypotension with persistently high left ventricular pressures. These high intraventricular pressures would make the left ventricle particularly vulnerable to the decrease in coronary pressure that occurs as a result of the systemic hypotension. Thus, primary arrhythmic death or increased left ventricular filling pressures and pulmonary edema might be precipitated.
Sudden Death
That these mechanisms are not entirely theoretical is suggested by the 11 patients who had fatal (three patients) or serious (eight patients) hemodynamic complications from oral verapamil (tables 2 and 3). Patients with hypertrophic cardiomyopathy die as a natural consequence of their disease, often making it difficult to attribute unequivocally a causal role of any LV assure initiation of verapamil treatment alone in three patients, after the addition of verapamil to quinidine in one patient, and after the addition of quinidine to verapamil in two patients. It is difficult to generalize from such a small series of patients, but some features bear emphasis. Most important, all but three of the 11 patients had either a history indicative of severely elevated pulmonary venous pressures or had pulmonary venous pressures of 20 mm Hg more as measured at catheterization. This proportion represents a disparately high percentage of patients who were treated chronically with verapamil. In addition, of the six patients in whom verapamil blood level measurements were made, only one patient who had a serious complication believed to be due to verapamil had an excessively high level of the drug. 
Survival
Abbreviations: SOBshortness of breath; Pulm edema = pulmonary edema; PND paroxysmal nocturnal dyspnea; Pt = patient; PCW = mean pulmonary capillary wedge pressure; LVOT = left ventricular outflow tract; SAM = systolic anterior motion of the mitral valve; CHF = congestive heart failure; -90 = effect of provocation on gradient.
Although all but one patient with serious complications had marked obstruction to left ventricular outflow either at rest or with provocation, firm conclusions cannot be drawn from this observation, because most of the patients we have treated have had the obstructive form of the disease.
In our current series, other less catastrophic complications have occurred that we believe were due to verapamil (table 1) : sinus arrest, sinus bradycardia with junctional escape rhythm and isorhythmic dissociation, and type I and II second-degree AV block. Approximately 17% of patients manifested electrophysiologic side effects during initiation of verapamil treatment. Moreover, three patients (3%) developed postural hypotension (without associated pulmonary edema) during oral administration of verapamil (in the absence of quinidine). Because of the close relation between onset of hypotension and initiation of verapamil treatment, as well as disappearance of hypotension upon reduction of verapamil dosage, the hypotension appears likely to be drug-regulated. Although patients may experience significant symptoms in association with these electrophysiologic and hemodynamic effects, only rarely does the drug have to be discontinued because of persisting abnormalities despite a decrease in dosage. However, each of these side effects, by predisposing to hypotension, has the potential of causing more serious hemodynamic complications ( fig. 3 ).
Three patients developed significant hypotension when verapamil was administered in conjunction with quinidine, and two of the three developed acute pulmonary edema coincident with the hypotension (table 3) . Further studies must be performed to determine whether quinidine and other antiarrhythmic drugs do exacerbate the deleterious hemodynamic effects of verapamil. Until definitive studies are available, however, their concomitant use should be undertaken only with extreme caution.
In conclusion, verapamil may lead to serious hemodynamic complications in patients with hypertrophic cardiomyopathy. Such serious complications probably occur rarely, but their incidence may be further reduced by careful selection of patients.
Based on our observations, we have tentatively adopted the following policy regarding the administration of verapamil to patients with hypertrophic cardiomyopathy:
The drug probably is contraindicated in patients who have: (1) high pulmonary capillary wedge pressures in the presence of obstruction to left ventricular outflow; (2) a history of paroxysmal nocturnal dyspnea or orthopnea in the presence of obstruction to left ventricular outflow; (3) sick sinus syndrome without an implanted pacemaker; and (4) significant AV junctional disease without an implanted pacemaker.
The drug should be given only when other alternatives are unavailable and only with extreme caution to patients with (1) high pulmonary capillary wedge pressures in the absence of obstruction to left ventricular outflow; (2) a history of paroxysmal nocturnal dyspnea or orthopnea in the absence of obstruction to left ven-tricular outflow; and (3) low systolic blood pressure, particularly in the presence of left ventricular outflow obstruction.
The drug can probably be given, but with caution, to patients with (1) systolic hypertension and marked obstruction to left ventricular outflow ( fig. 2 ) and (2) moderate prolongation of the PR interval on the ECG.
